Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 16, Issue 1, 2015, Pages 119-125

  Rossi, Rosario ^a   Crupi, Nicola ^a   Coppi, Francesca ^a   Monopoli, Daniel ^a   Sgura, Fabio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

ACE I: angiotensinconverting enzyme inhibitor; aldosterone; AMI: acute myocardial infarction; ARA: aldosterone receptor antagonist; ARB: angiotensin receptor antagonist; HF: heart failure; LV: left ventricular; mortality; MRA: mineralocorticoid receptor antagonist; prognosis; RAAS: renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANRENOATE POTASSIUM; CANRENONE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE; WARFARIN; CANRENOIC ACID;

AGED; ARTICLE; CONGESTIVE HEART FAILURE; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; PROGNOSIS; SURVIVAL; ADULT; COHORT ANALYSIS; HEART FAILURE; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CANRENOIC ACID; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROGNOSIS; SPIRONOLACTONE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84924954632     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320313482603     Document Type: Article

References (42)

1. Packer M. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992; 20: 248-254
2. Levine TB, Francis GS, Goldsmith SR, et al. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. Am J Cardiol. 1982; 49: 1659-1666
3. Mann DL. Mechanisms and models in heart failure. A combinatorial approach. Circulation. 1999; 100: 999-1008
4. Dzau VJ, Bernstein K, Celermajer D, et al. Pathophysiologic and therapeutic importance of tissue ACE: A consensus report. Cardiovasc Drugs Ther. 2002; 16: 149-160
5. Liu JL, Zucker IH. Regulation of sympathetic nerve activity in heart failure: A role for nitric oxide and angiotensin II. Circ Res. 1999; 84: 417-423
6. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling - concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol. 2000; 35: 569-582
7. White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987; 76: 44-51
8. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327: 685-691
9. Wang TJ, Levy D, Benjamin EJ, et al. The epidemiology of 'asymptomatic' left ventricular systolic dysfunction: Implications for screening. Ann Intern Med. 2003; 138: 907-916
10. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction. The CHARM-Preserved trial. Lancet. 2003; 362: 777-781
11. Struthers AD. Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J. 1995; 16: 103-106
12. Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy. Cardiovasc Drugs Ther. 1995; 9: 145-149
13. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001; 37: 1228-1233
14. Modena MG, Aveta P, Menozzi A, et al. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J. 2001; 141: 41-46
15. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341: 709-717
16. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364: 11-21
17. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with LV dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-1321
18. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119: e391 - e479
19. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012; 33: 1787-1847
20. Adamopoulos C, Ahmed A, Fay R, et al. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: Insights from the EPHESUS trial. Eur J Heart Fail. 2009; 11: 1099-1105
21. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003; 107: 2559-2565
22. Sligl W, McAlister FA, Ezekowitz J, et al. Usefulness of spironolactone in a specialized heart failure clinic. Am J Cardiol. 2004; 94: 443-447
23. Joynt KE, Orav EJ, Jha AK. The association between hospital volume and processes, outcomes and costs of care for congestive heart failure. Ann Intern Med. 2011; 15: 94-102
24. Stukel TA, Fisher ES, Alter DA, et al. Association of hospital spending intensity with mortality and readmission rates in Ontario hospitals. JAMA. 2012; 307: 1037-1045
25. Struthers AD. Aldosterone blockade in heart failure. J Renin Angiotensin Aldosterone Syst. 2004; 5: S23 - S27
26. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insight from the randomized aldactone evaluation study (RALES). Circulation. 2000; 102: 2700-2706
27. O'Keefe JH, Abuissa H, Pitt B. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: Results from EPHESUS. Diabetes Obes Metab. 2008; 10: 492-497
28. Boccanelli A, Mureddu GF, Cacciatore G, et al. Anti- remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): Final results. Eur J Heart Fail. 2009; 11: 68-76
29. MacFadyen RJ, Lee AF, Morton JJ, et al. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?. Heart. 1999; 82: 57-61
30. Borghi C, Boschi S, Ambrosioni E, et al. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol. 1993; 33: 40-45
31. Lee AF, MacFadyen RJ, Struthers AD. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: A longitudinal study. Eur J Heart Fail. 1999; 1: 401-406
32. Roig E, Perez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 2000; 21: 53-57
33. Tang WH, Vagelos RH, Yee YG, et al. Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol. 2002; 39: 70-78
34. Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail. 2004; 6: 539-545
35. McKelvie R, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction. Circulation. 1999; 100: 1056-1064
36. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000; 101: 594-597
37. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316: 1429-1435
38. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325: 293-302
39. Gardiner P. Spironolactone and potassium canrenoate metabolism. Lancet. 1985; 2: 1432
40. Sadee W, Dagcioglu M, Schroder R. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J Pharmacol Exp Ther. 1973; 185: 686-695
41. L'uso dei farmaci in Italia. Rapporto Nazionale anno 2011. Roma: Il Pensiero Scientifico Editore; 2012: 165.
42. de Simone G, Chinali M, Mureddu GF, et al. Effect of canrenone on left ventricular mechanics in patients with systolic heart failure and metabolic syndrome. Nutr Metab Cardiovasc Dis. 2011; 21: 783-791